Paper
Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
Published Sep 1, 2019 · Michael Miller, C. Ballantyne, H. Bays
The American journal of cardiology
Q1 SJR score
41
Citations
4
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
RCTStudy Snapshot
Icosapent ethyl significantly reduces triglycerides and inflammation in statin-treated patients with elevated high-sensitivity C-reactive protein and TG 200 to 499 mg/dl without increasing LDL-C.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Icosapent ethyl significantly reduces the risk of ischemic events in patients with elevated triglyceride levels, even in those receiving statin therapy.
2019·2081citations·Deepak L. Bhatt et al.·The New England Journal of Medicine
The New England Journal of Medicine
Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis
Icosapent ethyl 4g/day effectively reduced potentially atherogenic parameters in women with diabetes mellitus type 2 and persistently high triglycerides on statins, with safety and tolerability comparable to placebo.
2018·13citations·E. Brinton et al.·Journal of Women's Health
Journal of Women's Health
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Canakinumab at a dose of 150 mg every 3 months significantly reduced the rate of recurrent cardiovascular events in patients with atherosclerotic disease, without affecting lipid levels.
2017·6329citations·P. Ridker et al.·The New England Journal of Medicine
The New England Journal of Medicine
Potential benefits of eicosapentaenoic acid on atherosclerotic plaques.
Eicosapentaenoic acid (EPA) may reduce atherosclerotic plaque vulnerability and prevent plaque progression, potentially reducing cardiovascular risk in high-risk patients receiving statin therapy.
2017·75citations·J. Nelson et al.·Vascular pharmacology
Vascular pharmacology
Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
Icosapent ethyl 4g/day significantly reduced triglyceride levels and other atherogenic parameters in women without increasing low-density lipoprotein cholesterol levels compared to placebo.
2017·16citations·L. Mosca et al.·The American journal of cardiology
The American journal of cardiology
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Icosapent ethyl 4g/day significantly reduced both calculated and directly measured remnant-like particle cholesterol levels compared to placebo in patients with elevated triglyceride levels.
2016·42citations·C. Ballantyne et al.·Atherosclerosis
Atherosclerosis
Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis.
Eicosapentaenoic acid (EPA) shows potential as an adjunctive therapy for reducing residual cardiovascular risk in dyslipidemic patients, with beneficial effects on endothelial function, oxidative stress, plaque formation, and rupture.
2015·162citations·K. Borow et al.·Atherosclerosis
Atherosclerosis
Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).
Icosapent ethyl 4g/day for 12 weeks significantly reduced key atherogenic lipoprotein particle concentrations in statin-treated patients with persistent high triglycerides, with atherogenic lipoprotein concentrations correlating to apolipoprotein B.
2015·39citations·C. Ballantyne et al.·Journal of clinical lipidology
Journal of clinical lipidology
Citations
Native and pregelatinized potato and rice starches and maltodextrin as encapsulating agents for linseed oil ethyl esters – Comparison of emulsion and powder properties
Pregelatinized potato starch shows potential as a replacement for maltodextrin in encapsulating linseed oil ethyl esters due to its high encapsulation efficiency and reduced release of oxidation-related volatiles.
2023·7citations·Dorota Ogrodowska et al.·Journal of Food Engineering
Journal of Food Engineering
Fish Oil Derivatives in Hypertriglyceridemia: Mechanism and Cardiovascular Prevention: What do studies say?
Fish oil supplements may reduce the risk of cardiovascular diseases in hypertriglyceridemia patients, but the underlying mechanism and extent of reduction in CVD need further clarification.
2023·1citation·Muhammed I. Erbay et al.·Current problems in cardiology
Current problems in cardiology
Icosapent ethyl (VASCEPA®) as treatment for post-acute sequelae of SARS CoV-2 (PASC) vaccine induced injury and infection
Icosapent Ethyl may help resolve Long COVID symptoms in adults, suggesting its potential as a treatment for post-infectious syndromes.
2023·0citations·Sean M. Cruess et al.·Journal of Complementary and Integrative Medicine
Journal of Complementary and Integrative Medicine
Clinical results and mechanism of action of icosapent ethyl
Icosapent ethyl significantly reduces cardiovascular risk and atheromatous plaque progression, with potential mechanisms beyond triglyceride reduction.
2023·3citations·C. Borghi et al.·European Heart Journal Supplements : Journal of the European Society of Cardiology
European Heart Journal Supplements : Journal of the European Society of Cardiology
Remnant cholesterol in Atherosclerotic Cardiovascular disease: A Systematic Review and Meta-analysis.
Remnant cholesterol levels are associated with atherosclerotic cardiovascular disease risk, and lipid-lowering therapies tend to decrease these levels, but the clinical relevance of this decrease requires further investigation.
2023·8citations·D. Delialis et al.·Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
RETRACTED: Cardiovascular outcomes of ethyl eicosapentaenoic acid in diabetes mellitus: A meta-analysis
Ethyl eicosapentaenoic acid (EEA) showed no significant cardiovascular benefits in diabetes mellitus patients, as evidenced by the retraction of this article due to incomplete and misleading data.
2022·2citations·Yasar Sattar et al.·Annals of Medicine and Surgery
Annals of Medicine and Surgery